ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "GTx, Inc." (GTXI) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"GTx, Inc." (GTXI)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: ANAC, ATNM, INSY, BCRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"GTx, Inc."© quotemedia

Company Profile

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women primarily through wholesale drug distributors in the United States. It is also developing Enobosarm, an anabolic agent, which is in Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. The company’s preclinical stage products include inhibitors of steroid biosynthetic enzymes, anticancer therapies, estrogen receptor beta agonists, and other novel compounds for the treatment of cancer, metabolic diseases, ophthalmic diseases, psoriasis, and/or pain. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.

Recent News: "GTx, Inc."